Zentalis Pharmaceuticals (ZNTL)
(Delayed Data from NSDQ)
$3.31 USD
+0.03 (0.91%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $3.30 -0.01 (-0.30%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ZNTL 3.31 +0.03(0.91%)
Will ZNTL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ZNTL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZNTL
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold
ZNTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet
Down -19.06% in 4 Weeks, Here's Why You Should You Buy the Dip in Zentalis Pharmaceuticals, Inc. (ZNTL)
What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock
Other News for ZNTL
Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress
Zentalis sees cash runway into mid-2026
Zentalis CMO Diana Hausman steps down
Zentalis discontinuing development of ZN-d5
Zentalis reports Q2 EPS ($1.24), consensus (84c)